Loading clinical trials...
Loading clinical trials...
The primary purpose of this study is to determine the safety and efficacy of oral RG2417 (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Repligen Corporation
NCT07172516 · Bipolar Disorder, Bipolar Depression, and more
NCT06370988 · Bipolar Depression, Bipolar Disorder, and more
NCT04480918 · Treatment Resistant Depression, Major Depressive Episode, and more
NCT06524505 · Bipolar Depression
NCT06599099 · Bipolar Depression
Stanford University
Stanford, California
Carman Research
Smyrna, Georgia
Indiana University-Purdue University Indianapolis
Indianapolis, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions